Go to Main

– Development of a next-generation gene therapy strategy based on ROS-responsive hydrogels –

The research team led by Professor Eun-Jung Jin(CEO of Organelle Therapeutics Inc.), in collaboration with a research team from Korea National University of Transportation, has developed a next-generation gene therapy strategy capable of effectively preventing 'renal fibrosis,' a core lesion of chronic kidney disease.

This achievement has been published in the latest issue of Advanced Healthcare Materials (JCR Top 8.87%, Impact Factor: 9.6), a world-renowned journal in the fields of materials and healthcare, gaining recognition for its academic excellence.

This study is highly significant as it successfully demonstrated 'dual therapeutic effects' in animal models, inhibiting the progression of renal fibrosis through multiple mechanisms by combining the Pygo2-targeted gene silencing effect with the environment-responsive properties of the ROS-responsive hydrogel. Furthermore, as a universal platform technology applicable to chronic fibrotic diseases occurring in various organs such as the liver and lungs, it is expected to be utilized as an innovative original technology in the future anti-fibrotic drug market.

Resource: https://v.daum.net/v/20260119095924611